An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab.

Trial Profile

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CARE-MS Extension Study; CARE-MS II Extension Study
  • Sponsors Genzyme Corporation; Sanofi Genzyme
  • Most Recent Events

    • 23 Aug 2017 Results assessing 5-year follow up outcomes in patients completing CARE-MS I and enrolling in the extension study published in the Neurology.
    • 23 Aug 2017 Interim safety and efficacy results of CARE-MS II patients through 3 years of this extension study (n=393) published in the Neurology
    • 27 Jun 2017 4-year MRI outcomes were presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top